Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Operating Income: 2023-2024

Historic Operating Income for Artiva Biotherapeutics (ARTV) over the last 2 years, with Dec 2024 value amounting to -$18.3 million.

  • Artiva Biotherapeutics' Operating Income fell 52.61% to -$18.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$67.3 million, marking a year-over-year change of. This contributed to the annual value of -$67.3 million for FY2024, which is 119.37% down from last year.
  • As of Q4 2024, Artiva Biotherapeutics' Operating Income stood at -$18.3 million, which was up 0.37% from -$18.3 million recorded in Q3 2024.
  • Artiva Biotherapeutics' 5-year Operating Income high stood at $10.8 million for Q3 2023, and its period low was -$18.3 million during Q3 2024.
  • Over the past 2 years, Artiva Biotherapeutics' median Operating Income value was -$16.2 million (recorded in 2024), while the average stood at -$12.3 million.
  • The largest annual percentage gain for Artiva Biotherapeutics' Operating Income in the last 5 years was 8.46% (2024), contrasted with its biggest fall of 269.60% (2024).
  • Artiva Biotherapeutics' Operating Income (Quarterly) stood at -$12.0 million in 2023, then tumbled by 52.61% to -$18.3 million in 2024.
  • Its last three reported values are -$18.3 million in Q4 2024, -$18.3 million for Q3 2024, and -$16.2 million during Q2 2024.